Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
RNA interference (RNAi) is a universal and evolutionarily conserved phenomenon of post-transcriptional gene silencing by means of sequence-specific mRNA degradation, triggered by small double-stranded RNAs. Because this mechanism can be efficiently induced in vivo by expressing target-complementary short hairpin RNA (shRNA) from non-viral and viral vectors, RNAi is attractive for functional genomics and human therapeutics. Here we systematically investigate the long-term effects of sustained high-level shRNA expression in livers of adult mice. Robust shRNA expression in all the hepatocytes after intravenous infusion was achieved with an optimized shRNA delivery vector based on duplex-DNA-containing adeno-associated virus type 8 (AAV8). An evaluation of 49 distinct AAV/shRNA vectors, unique in length and sequence and directed against six targets, showed that 36 resulted in dose-dependent liver injury, with 23 ultimately causing death. Morbidity was associated with the downregulation of liver-derived microRNAs (miRNAs), indicating possible competition of the latter with shRNAs for limiting cellular factors required for the processing of various small RNAs. In vitro and in vivo shRNA transfection studies implied that one such factor, shared by the shRNA/miRNA pathways and readily saturated, is the nuclear karyopherin exportin-5. Our findings have fundamental consequences for future RNAi-based strategies in animals and humans, because controlling intracellular shRNA expression le…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cellular toxicity can, for example, be observed in rAAV shRNA overexpression studies in which ubiquitous promoters were used that caused saturation of cellular miRNA pathways [88].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“However, the relatively large size, the requirement that the transcript starts with a G or A, the sometimes too active transcription, and the sensitivity to specific cellular profiles make the human U6 promoter a less versatile promoter [88,131,132].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“Consistent with this possibility, when multiple miRNAs are packaged within a single construct, they may compete for processing by the cellular miRNA biogenesis machinery, leading to reduced efficiency in individual miRNA maturation and function 44,45 .”
From rAAV-mediated Multi-miRNA Delivery Targeting MAPK Pathway Suppresses Laser-induced Choroidal Neovascularization in Mice (2026) · cites this paper as [44]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
Identification of tissue-specific microRNAs from mouse
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00809-6 · Cited by 3,355
Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs
Yi, R., Qin, Y., Macara, I. G., & Cullen, B. R. (2003) · Genes & Development · doi:10.1101/gad.1158803 · Cited by 3,010
Nuclear Export of MicroRNA Precursors
Lund, E., Güttinger, S., Calado, A., Dahlberg, J. E., & Kutay, U. (2004) · Science · doi:10.1126/science.1090599 · Cited by 2,714
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA
Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., & Sarnow, P. (2005) · Science · doi:10.1126/science.1113329 · Cited by 2,521
Self-citationExportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs
BOHNSACK, M. T., CZAPLINSKI, K., & GÖRLICH, D. (2004) · RNA · doi:10.1261/rna.5167604 · Cited by 1,433
Cited by
Items 301–400 of 1,001
Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells
Vickers, T. A., Lima, W. F., Nichols, J. G., & Crooke, S. T. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm663 · Cited by 91
ETMR: a tumor entity in its infancy
Lambo, S., von Hoff, K., Korshunov, A., Pfister, S. M., & Kool, M. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02182-2 · Cited by 97
Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract
Kriegel, C., Attarwala, H. Z., & Amiji, M. M. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.11.003 · Cited by 94
Sapountzis, P., Duport, G., Balmand, S., Gaget, K., Jaubert‐Possamai, S., Febvay, G., Charles, H., Rahbé, Y., Colella, S., & Calevro, F. (2014) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2014.05.005 · Cited by 100
“The observed high dose toxicity of dsRNA has been previously, and in other model systems, attributed to a non-specific saturation of RNAi machinery causing a consequent alteration of the microRNA pathway (Grimm et al., 2006).”
BackgroundShort Hairpin RNA Interference Therapy for Ischemic Heart Disease
Huang, M., Chan, D. A., Jia, F., Xie, X., Li, Z., Hoyt, G. E., Robbins, R. C., Chen, X. S., Giaccia, A. J., & Wu, J. C. (2008) · Circulation · doi:10.1161/circulationaha.107.760785 · Cited by 103
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“Cellular toxicity can, for example, be observed in rAAV shRNA overexpression studies in which ubiquitous promoters were used that caused saturation of cellular miRNA pathways [88].”
BackgroundMolecular Strategies to Target Protein Aggregation in Huntington’s Disease
Jarosińska, O. D., & Rüdiger, S. G. D. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.769184 · Cited by 90
Mendonça, L. S., Firmino, F., Moreira, J. N., Pedroso de Lima, M. C., & Simões, S. (2010) · Bioconjugate Chemistry · doi:10.1021/bc9004365 · Cited by 90
Role of microRNAs in hepatitis B virus replication and pathogenesis
Liu, W., Yeh, S., & Chen, P. (2011) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2011.04.008 · Cited by 97
Regulated and Multiple miRNA and siRNA Delivery Into Primary Cells by a Lentiviral Platform
Amendola, M., Passerini, L., Pucci, F., Gentner, B., Bacchetta, R., & Naldini, L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.48 · Cited by 92
Advances with RNAi-Based Therapy for Hepatitis B Virus Infection
van den Berg, F. T., Limani, S. W., Mnyandu, N., Maepa, M. B., Ely, A., & Arbuthnot, P. B. (2020) · Viruses · doi:10.3390/v12080851 · Cited by 93
“A caveat of strong shRNA expression is that endogenous miRNA processing may be disrupted to cause severe toxicity in mice [54].”
BackgroundA genome-wide transgenic resource for conditional expression of Drosophila microRNAs
Bejarano, F., Bortolamiol-Becet, D., Dai, Q., Sun, K., Saj, A., Chou, Y.-T., Raleigh, D. R., Kim, K., Ni, J.-Q., Duan, H., et al. (2012) · Development · doi:10.1242/dev.079939 · Cited by 89
“…reflect the consequences of miRNA-guided target regulation, as opposed to saturating the miRNA biogenesis pathway, as has been observed in other experimental systems (Grimm et al., 2006); such an outcome would have been manifest as non-specific phenotypes that were common to most miRNA transgenes.”
ResultRNA interference as a gene knockdown technique
Shan, G. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.04.023 · Cited by 97
Specific Inhibition of HBV Replication In Vitro and In Vivo With Expressed Long Hairpin RNA
Weinberg, M. S., Ely, A., Barichievy, S., Crowther, C. E., Mufamadi, M. S., Carmona, S., & Arbuthnot, P. B. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300077 · Cited by 88
Nucleic acid therapeutics: basic concepts and recent developments
Sharma, V. K., Rungta, P., & Prasad, A. K. (2014) · RSC Advances · doi:10.1039/c3ra47841f · Cited by 91
Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles
Peer, D. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.06.013 · Cited by 91
Pei, Y., Wang, C., Yan, S. F., & Liu, G. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01442 · Cited by 88
Pavani, G., Fabiano, A., Laurent, M., Amor, F., Cantelli, E., Chalumeau, A., Maule, G., Tachtsidi, A., Concordet, J., Cereseto, A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020001996 · Cited by 104
The regulatory roles of non-coding RNAs in nerve injury and regeneration
Yu, B., Zhou, S., Yi, S., & Gu, X. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.006 · Cited by 89
The Business of RNAi Therapeutics
Haussecker, D. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.007 · Cited by 97
Design of extended short hairpin RNAs for HIV-1 inhibition
Liu, Y. P., Haasnoot, J., & Berkhout, B. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm596 · Cited by 86
“Notably, cytotoxicity can also be induced by overexpression of shRNAs, which leads to competition for and oversaturation of endogenous cellular RNAi components (38).”
BackgroundRNAi and Gene Therapy: A Mutual Attraction
Grimm, D., & Kay, M. A. (2007) · Hematology · doi:10.1182/asheducation-2007.1.473 · Cited by 102
“This became particularly apparent in our own recent study, where we overexpressed shRNAs in the murine liver from an optimized and utmost efficient AAV serotype 8 vector.(16) In fact, transduction by this vector (when used at high doses) was so efficient that the encoded shRNAs saturated the endogenous hepatic miRNA p…”
BackgroundSelf-citationEhlert, E. M., Eggers, R., Niclou, S. P., & Verhaagen, J. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-20 · Cited by 86
“This saturation can be reversed by overexpression of Exportin-5 enhancing shRNA and endogenous miRNA activity in vitro [34] and in vivo [22].”
BackgroundInfluentialRoss, K. A., Smyth, N. A., Murawski, C. D., & Kennedy, J. G. (2013) · ISRN Oncology · doi:10.1155/2013/759725 · Cited by 85
“However, due to the fact that these types of therapeutics are challenging to administer pharmacologically, they are not necessarily applicable clinically, and several groups have asserted that the next reasonable step is focusing on proteinprotein interactions rather than the ESFT genes themselves [15, 37, 74].”
BackgroundMawji, I. A., Simpson, C. D., Hurren, R., Gronda, M., Williams, M. A., Filmus, J., Jonkman, J. E. N., Costa, R. S. D., Wilson, B. C., Thomas, M. P., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk182 · Cited by 86
CRISPR genome engineering and viral gene delivery: A case of mutual attraction
Schmidt, F., & Grimm, D. (2015) · Biotechnology Journal · doi:10.1002/biot.201400529 · Cited by 84
Self-citationEnjoy the Silence: The Story of let-7 MicroRNA and Cancer
Torrisani, J., Parmentier, L., Buscail, L., & Cordelier, P. (2007) · Current Genomics · doi:10.2174/138920207781386933 · Cited by 91
“As a consequence, normal cellular pre-miRNAs processing was inhibited, as their cytoplasmic maturation, and function, leading to cell death [57].”
BackgroundBoudreau, R. L., Spengler, R. M., & Davidson, B. L. (2011) · Molecular Therapy · doi:10.1038/mt.2011.185 · Cited by 84
Nunes, F. M. F., & Simões, Z. L. P. (2008) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2008.10.011 · Cited by 94
RNAi mechanisms in Huntington’s disease therapy: siRNA versus shRNA
Aguiar, S. P., van der Gaag, B., & Cortese, F. A. B. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0101-9 · Cited by 92
“[34] demonstrated that an shRNA targeted to the liver caused hepatic cytotoxicity due to high level, sustained expression in mice (the empty AAV vectors were nontoxic at doses used).”
BackgroundAronin, N., & DiFiglia, M. (2014) · Movement Disorders · doi:10.1002/mds.26020 · Cited by 81
“Loss of exportin-5 function may be toxic.(27) Safety of AAV-delivered miRNA depends on the extent of miRNA expression and selectivity in targeting.”
BackgroundModeling CRISPR-Cas13d on-target and off-target effects using machine learning approaches
Cheng, X., Li, Z., Shan, R., Li, Z., Wang, S., Zhao, W., Zhang, H., Chao, L., Peng, J., Teng, F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36316-3 · Cited by 98
“For example, the overexpression of short hairpin RNA (shRNA) damages cell viability by disrupting the miRNA processing in host cells 27 .”
BackgroundImproving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors
Herrera-Carrillo, E., Liu, Y. P., & Berkhout, B. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.036 · Cited by 86
MicroRNAs and the Regulation of Vector Tropism
Kelly, E. J., & Russell, S. J. (2009) · Molecular Therapy · doi:10.1038/mt.2008.288 · Cited by 82
Molecular dissection of human Argonaute proteins by DNA shuffling
Schürmann, N., Trabuco, L. G., Bender, C., Russell, R. B., & Grimm, D. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2607 · Cited by 94
Self-citationDefining Features and Exploring Chemical Modifications to Manipulate RNAa Activity
Place, R. F., Noonan, E. J., Földes‐Papp, Z., & Li, L. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110791591463 · Cited by 83
“Moreover, the longerlasting effect of RNAa may result in less frequent administration of saRNA; a potential benefit as duplex RNA in excess can have toxic consequences [29].”
m RNA trans ‐splicing in gene therapy for genetic diseases
Berger, A., Maire, S., Gaillard, M., Sahel, J., Hantraye, P., & Bemelmans, A. (2016) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1347 · Cited by 82
“Splicing, a reaction occurring in the nucleus of eukaryotic cells, is catalyzed by the spliceosome, one of the largest ribonucleoproteic complex of the cell, and results in the elimination of intronic sequences from pre-mRNA.”
InfluentialSynthetic AAV/CRISPR vectors for blocking HIV‐1 expression in persistently infected astrocytes
Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov‐Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., et al. (2018) · Glia · doi:10.1002/glia.23254 · Cited by 79
“All AAV vectors contained a cytomegalovirus (CMV) promoter-driven reporter gene encoding the enhanced yellow fluorescence protein (EYFP; Grimm et al., 2006).”
BackgroundSelf-citationSafe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques
Borel, F., Gernoux, G., Sun, H., Stock, R., Blackwood, M., Brown, R. H., & Mueller, C. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aau6414 · Cited by 78
“We speculate that it reflects the fact that the RNAi-mediating molecule of choice is an artificial miRNA and not a short hairpin RNA; the latter has been associated with cellular miRNA-related toxicity in previous reports (22, 23).”
BackgroundResultSilencing strategies for therapy of SOD1-mediated ALS
van Zundert, B., & Brown, R. H. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.07.059 · Cited by 84
siRNA therapeutics and its challenges: Recent advances in effective delivery for cancer therapy
Paul, A., Muralidharan, A., Biswas, A., Kamath, B. V., Joseph, A., & Alex, A. T. (2022) · OpenNano · doi:10.1016/j.onano.2022.100063 · Cited by 83
Progress and prospects: RNA-based therapies for treatment of HIV infection
Scherer, L. J., Rossi, J. J., & Weinberg, M. S. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302977 · Cited by 95
Minimal-length short hairpin RNAs: The relationship of structure and RNAi activity
Ge, Q., Ilves, H., Dallas, A., Kumar, P., V, Shorenstein, J., Kazakov, S. A., & Johnston, B. H. (2009) · RNA · doi:10.1261/rna.1894510 · Cited by 88
“Among these, shRNA has received considerable attention due to its wide spread use in DNA vector-based applications—such as shRNA libraries for various loss-of-function screens, cell lines, transgenic animals that express silencing triggers against targets of interest, and therapeutic approaches (Xia et al. 2002; Xia e…”
BackgroundHaussecker, D., & Kay, M. A. (2015) · Science · doi:10.1126/science.1252967 · Cited by 80
Self-citationOh, W., Yang, Y.-S., Xie, J., Ma, H., Kim, J., Park, K. H., Oh, D. S., Park‐Min, K., Greenblatt, M. B., Gao, G., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.018 · Cited by 82
“…short hairpin RNAs (shRNAs) may induce cytotoxicity by perturbing RNA interference machinery or exhibit signi fi cant off-target silencing, 24,25 an AAV-compatible amiR was developed by embedding the guide strand of a small silencing RNA that targets Sost or Shn3 into a mouse…”
Dubreuil, M. M., Morgens, D. W., Okumoto, K., Honsho, M., Contrepois, K., Lee-McMullen, B., Traber, G. M., Sood, R. S., Dixon, S. J., Snyder, M. P., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.013 · Cited by 79
“We and others have shown that KO and knockdown screen technologies often reveal distinct gene signatures because of differences in strength of on-target activity, off-target effects, efficacies of gene-targeting elements between libraries, compensatory mechanisms, and the ability to target essential genes (Barrangou e…”
BackgroundKumar, N., Stanford, W., de Solis, C., Aradhana, Abraham, N. D., Dao, T.-M. J., Thaseen, S., Sairavi, A., Gonzalez, C. U., & Ploski, J. E. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00413 · Cited by 79
MicroRNAs: Novel Players in Cancer Diagnosis and Therapies
Oom, A. L., Humphries, B. A., & Yang, C. (2014) · BioMed Research International · doi:10.1155/2014/959461 · Cited by 81
“The group found that miRNAs and shRNAs were competing for cellular processing equipment leading to a buildup of premature miRNAs and shRNAs [142].”
BackgroundEly, A., Naidoo, T., & Arbuthnot, P. B. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp446 · Cited by 79
“This important property provides the means of improving control of production of RNAi activators and thereby limiting unwanted off target effects caused by saturating the endogenous miR pathway (8).”
BackgroundGelatin nanospheres incorporating siRNA for controlled intracellular release
Ishikawa, H., Nakamura, Y., Jo, J., & Tabata, Y. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.08.032 · Cited by 79
microRNAs in Adult Rodent Liver Are Refractory to Dioxin Treatment
Moffat, I. D., Boutros, P. C., Celius, T., Lindén, J., Pohjanvirta, R., & Okey, A. B. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm189 · Cited by 86
Risk associated with off-target plant genome editing and methods for its limitation
Zhao, H., & Wolt, J. D. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170037 · Cited by 78
Designing highly active siRNAs for therapeutic applications
Walton, S. P., Wu, M., Gredell, J. A., & Chan, C. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07903.x · Cited by 84
“While there is some concern that this machinery could be diverted from its normal roles by saturation with exogenous siRNAs [20], this would likely be a concern only for a chronic therapy, for which short, hairpin RNAs (shRNAs), which are related in structure and function to both siRNAs and miRNAs, are more suitable […”
BackgroundRegulation of microRNA biogenesis and turnover by animals and their viruses
Libri, V., Miesen, P., van Rij, R. P., & Buck, A. H. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1257-1 · Cited by 80
“Over-expression of short hairpin RNAs (shRNAs) in animals can also be toxic due to saturation of Exportin-5 and subsequent inhibition of pre-miRNA export [92].”
BackgroundContext-aware synthetic biology by controller design: Engineering the mammalian cell
Shakiba, N., Jones, R. D., Weiss, R., & Vecchio, D. D. (2021) · Cell Systems · doi:10.1016/j.cels.2021.05.011 · Cited by 87
Investigation of TRPV1 loss-of-function phenotypes in transgenic shRNA expressing and knockout mice
Christoph, T., Bahrenberg, G., Vry, J. D., Englberger, W., Erdmann, V. A., Frech, M. J., Kögel, B. Y., Röhl, T., Schiene, K., Schröder, W., et al. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.12.006 · Cited by 85
“Since no obvious behavioural side effects were observed, it is reasonable to assume that rosa26 is an appropriate locus for the insertion of expression cassettes without the risk of excessive, deleterious expression levels, which may occur after viral delivery of expression cassettes (Grimm et al., 2006).”
BackgroundTo, K. K. W. (2013) · Journal of Biomedical Science · doi:10.1186/1423-0127-20-99 · Cited by 84
“Indeed, a fatal side effect as a result of saturation of miRNA pathways has been reported in an animal study [133].”
BackgroundShort non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics
Weinberg, M. S., & Wood, M. J. A. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp070 · Cited by 74
RNA interference therapeutics in organ transplantation: The dawn of a new era
Brüggenwirth, I. M. A., & Martins, P. N. A. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15689 · Cited by 82
microRNAs: Modulators of the underlying pathophysiology of sarcopenia?
Brown, D. M., & Goljanek‐Whysall, K. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.08.007 · Cited by 86
Mussolino, C., Sanges, D., Marrocco, E., Bonetti, C., Di Vicino, U., Marigo, V., Auricchio, A., Meroni, G., & Surace, E. M. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201000119 · Cited by 74
“Moreover, as well as the off-target silencing events that will potentially set the hurdles for the development of a safe ZFP-based or RNAi-based system, studies have shown that high levels of siRNAs can cause cellular toxicity through various mechanisms (Boudreau et al, 2009; Grimm et al, 2006).”
BackgroundYang, Y., Jittayasothorn, Y., Chronis, D., Wang, X., Cousins, P. S., & Zhong, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069463 · Cited by 83
“Because of the potential opportunities of RNAi application in gene therapy, significant effort has been directed toward optimizing siRNA duplex sequences for achieving high potency, low toxicity and low off-target effect in medical research [30,31].”
BackgroundGene Therapy for Chronic HBV—Can We Eliminate cccDNA?
Bloom, K. M., Maepa, M. B., Ely, A., & Arbuthnot, P. B. (2018) · Genes · doi:10.3390/genes9040207 · Cited by 82
“Expressed or synthetic antiviral sequences may mimic primary microRNAs, precursor microRNAs, or mature microRNAs (miRs) [26] [27] [28] [29] .”
BackgroundCristofolini, T., Dalmina, M., Sierra, J. A., Silva, A. H., Pasa, A. A., Pittella, F., & Creczynski‐Pasa, T. B. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.110555 · Cited by 76
A simplified purification protocol for recombinant adeno-associated virus vectors
Potter, M., Lins, B., Mietzsch, M., Heilbronn, R., Van Vliet, K., Chipman, P., Agbandje-McKenna, M., Cleaver, B. D., Clément, N., Byrne, B. J., et al. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.34 · Cited by 73
Amelioration of Psoriasis by Anti-TNF-α RNAi in the Xenograft Transplantation Model
Jakobsen, M., Stenderup, K., Rosada, C., Moldt, B., Kamp, S., Dam, T. N., Jensen, T. G., & Mikkelsen, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.141 · Cited by 76
RNA interference: a chemist's perspective
Gaynor, J. W., Campbell, B. J., & Cosstick, R. (2010) · Chemical Society Reviews · doi:10.1039/b920362c · Cited by 91
MicroRNA in Lung Cancer Metastasis
Wu, S., Chang, T., Liu, Y., & Shih, J. (2019) · Cancers · doi:10.3390/cancers11020265 · Cited by 75
“In addition, recent reports revealed the toxicity related to miRNA therapies [376].”
BackgroundRALA-Mediated Delivery of FKBPL Nucleic Acid Therapeutics
Bennett, R., Yakkundi, A., McKeen, H. D., McClements, L., McKeogh, T. J., McCrudden, C. M., Arthur, K., Robson, T., & McCarthy, H. O. (2015) · Nanomedicine · doi:10.2217/nnm.15.115 · Cited by 76
The Therapeutic Potential of MicroRNAs: Disease Modulators and Drug Targets
McDermott, A. M., Heneghan, H., Miller, N., & Kerin, M. J. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0550-2 · Cited by 78
“Systemic administration of short RNAs was achieved in adult mice using a delivery vector based on duplex-DNA-containing adeno-associated virus type 8 (AAV8), resulting in down-regulation of critical liverderived miRNAs, resulting in morbidity and even fatalities (34).”
MethodAdvances in systemic siRNA delivery
Leng, Q., Woodle, M. C., Lu, P. Y., & Mixson, A. J. (2009) · Drugs of the Future · doi:10.1358/dof.2009.034.09.1413267 · Cited by 77
“Neuroimaging Clin N Am 2001;11 (4):727–735.”
Valdmanis, P. N., Kim, H. K., Chu, K., Zhang, F., Xu, J., Munding, E. M., Shen, J., & Kay, M. A. (2018) · Nature Communications · doi:10.1038/s41467-018-07786-7 · Cited by 72
Self-citationKeskin, S., Brouwers, C. C., Sogorb-González, M., Martier, R., Depla, J. A., Vallès, A., van Deventer, S. J. H., Konstantinova, P. S., & Evers, M. M. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.09.010 · Cited by 77
“This is thought to result from competition between the endogenous and engineered miRNAs for the intracellular factors and pathways that are needed for the processing of primary- and pre-miRNA.(18,19) Additional variables such as promoter strength may affect miRNA expression levels and protein knockdown,(20) and theref…”
BackgroundMolecular Pathways: MicroRNAs as Cancer Therapeutics
Melo, S. A., & Kalluri, R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2010 · Cited by 78
Goodchild, J. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-188-8_1 · Cited by 75
Makkar, S. K. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1675209 · Cited by 80
“Transcriptome-wide off-target assessment via high-throughput sequencing and bioinformatics pipelines allows empirical identi fi cation and minimization of unintended interactions (Fedorov et al., 2006; Grimm et al., 2006).”
Ulusoy, A., Şahin, G., Björklund, T., Aebischer, P., & Kirik, D. (2009) · Molecular Therapy · doi:10.1038/mt.2009.142 · Cited by 73
“9 They found that toxicity was associated with downregulation of endogenous miRNAs, which could be eliminated by reducing the viral titer.”
InfluentialChen, C.-C., Ko, T.-M., Ma, H.-I., Wu, H.-L., Xiao, X., Li, J., Chang, C.-M., Wu, P.-Y., Chen, C.-H., Han, J.-M., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302846 · Cited by 78
siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse
Boudreau, R. L., Spengler, R. M., Hylock, R. H., Kusenda, B. J., Davis, H., Eichmann, D. A., & Davidson, B. L. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks797 · Cited by 80
Ahmed, F., Senthil‐Kumar, M., Dai, X., Vemanna, R. S., Lee, S., Mysore, K. S., & Zhao, P. X. (2020) · PLANT PHYSIOLOGY · doi:10.1104/pp.20.00293 · Cited by 81
“…mixed and unknown features, such as noneffective, nonspeci fi c, and toxic siRNAs, which may cause nonfunctional and off-target gene silencing (Jackson et al., 2003; Jackson et al., 2006; Burchard et al., 2009), as well as cell toxicity (Yi et al., 2005; Grimm et al., 2006; Olejniczak et al., 2010).”
BackgroundMolecular therapy in the microRNA era
Würdinger, T., & Costa, F. F. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500429 · Cited by 75
Singh, N. P., Singh, U. P., Guan, H., Nagarkatti, P. S., & Nagarkatti, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045054 · Cited by 72
“Some of cellular processes regulated by miRs include apoptosis, cell growth, fat storage, insulin secretion, and cancer initiation and progression [4,5,6].”
BackgroundBunse, M., Bendle, G. M., Linnemann, C., Bies, L., Schulz, S., Schumacher, T. N., & Uckert, W. (2014) · Molecular Therapy · doi:10.1038/mt.2014.142 · Cited by 67
Oligonucleotide-based strategies to combat polyglutamine diseases
Fiszer, A., & Krzyżosiak, W. J. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku385 · Cited by 72
RNA Interference Technologies and Therapeutics: From Basic Research to Products
López‐Fraga, M., Martínez, T., & Jiménez, A. (2009) · BioDrugs · doi:10.2165/11318190-000000000-00000 · Cited by 73
“shRNAs also enter the endogenous silencing pathway at an earlier stage than siRNAs, having a higher chance of saturating the natural miRNA natural pathways.([29]) Recent studies have sought to address this issue by showing that it is possible to avoid at least some of the safety concerns by seeking localized expressio…”
BackgroundViral Vectors Applied for RNAi-Based Antiviral Therapy
Lundstrom, K. H. (2020) · Viruses · doi:10.3390/v12090924 · Cited by 70
“Another issue relates to the lethality due to acute liver failure observed in mice after tail vein injection of AAV-based shRNA delivery, which has required to carefully control the levels of ectopic expression of therapeutic shRNAs, as these can be processed into siRNAs eliciting off-target effects and competition wi…”
BackgroundSingle siRNA Nanocapsules for Enhanced RNAi Delivery
Yan, M., Liang, M., Wen, J., Liu, Y., Lu, Y., & Chen, I. S. Y. (2012) · Journal of the American Chemical Society · doi:10.1021/ja304649a · Cited by 69
In Vivo Delivery Aspects of miRNA, shRNA and siRNA
Khatri, N., Rathi, M. N., Baradia, D., Trehan, S., & Misra, A. R. (2012) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v29.i6.20 · Cited by 72
RNAi medicine for the brain: progresses and challenges
Boudreau, R. L., Rodríguez-Lebrón, E., & Davidson, B. L. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr137 · Cited by 80
“(30) reported that high-level shRNA expression, typical from strong Pol III promoters, in mouse liver caused fatality.”
BackgroundValidated MicroRNA Target Databases: An Evaluation
Ji (Diana) Lee, Y., Kim, V., Muth, D. C., & Witwer, K. W. (2015) · Drug Development Research · doi:10.1002/ddr.21278 · Cited by 67
“Excess RNA might saturate the RNA silencing machinery, preventing normal regulation of endogenous genes by endogenous small RNAs [Grimm et al., 2006; Jackson and Linsley, 2010; Grimm, 2011].”
BackgroundCuciniello, R., Filosa, S., & Crispi, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02193-1 · Cited by 78
“A common approach to resolve both events that determine off-targets is the use of the minimum possible concentration of siRNA, as the previous mechanisms are dependent from the concentration [74].”
BackgroundTherapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy
Bisset, D., Stępniak-Konieczna, E., Zavaljevski, M., Wei, J., Carter, G. T., Weiss, M. D., & Chamberlain, J. R. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv219 · Cited by 75
Hypoxia as a target for tissue specific gene therapy
Rhim, T., Lee, D. Y., & Lee, M. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.021 · Cited by 66
Gene Therapy with Helper-Dependent Adenoviral Vectors: Current Advances and Future Perspectives
Vetrini, F., & Ng, P. (2010) · Viruses · doi:10.3390/v2091886 · Cited by 77
“In preclinical studies for liver-directed gene therapy, AAV vectors, similarly to HDAd, have shown to provide long-term transgene expression in mouse, dog and non human primates [87,87-91].”
BackgroundInfluentialThe Dicey Role of Dicer: Implications for RNAi Therapy
Merritt, W. M., Bar‐Eli, M., & Sood, A. K. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2536 · Cited by 78
“For example, Grimm and colleagues reported significant morbidity and mortality in murine models when administering shRNA viral vectors (26).”
BackgroundExpression Strategies for Short Hairpin RNA Interference Triggers
Rossi, J. J. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.026 · Cited by 79
Wallace, L. M., Saad, N. Y., Pyne, N. K., Fowler, A. M., Eidahl, J. O., Domire, J. S., Griffin, D. A., Herman, A., Sahenk, Z., Rodino‐Klapac, L. R., et al. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.12.005 · Cited by 67
“Previous pre-clinical studies suggested that vector-expressed RNAi triggers such as short hairpin RNAs (shRNAs) could potentially cause adverse effects by two mechanisms: overexpressionrelated toxicity through saturation of the natural microRNA biogenesis pathway and unintended sequence-specific silencing of off-targe…”
BackgroundOngoing Clinical Trials of Nonviral siRNA Therapeutics
Narasipura, E. A., VanKeulen‐Miller, R., Ma, Y., & Fenton, O. S. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00205 · Cited by 69
A holistic analysis of the intrinsic and delivery-mediated toxicity of siRNA therapeutics
Ranjbar, S., Zhong, X., Manautou, J. E., & Lü, X. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115052 · Cited by 72
Intron-mediated RNA interference and microRNA (miRNA)
Lin, S.-L. (2007) · Frontiers in bioscience · doi:10.2741/2836 · Cited by 70
Metadata
- Authors
- Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Universitätsklinikum Aachen (DE)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 537-541
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1971643509
- Cited by
- 1,677
- References
- 31
- Citations by year
- 2026: 27 · 2025: 32 · 2024: 49 · 2023: 35 · 2022: 57 · 2021: 36 · 2020: 45 · 2019: 54 · 2018: 54 · 2017: 60 · 2016: 75 · 2015: 94 · 2014: 92 · 2013: 121 · 2012: 121
- FWCI
- 57.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- RNA interference, shRNA, microRNA, XPO5, hepatotoxicity, liver injury, AAV8 vector, siRNA delivery, karyopherins, post-transcriptional gene silencing, mice, gene silencing therapy, dose-dependent toxicity
- MeSH terms
- Animals, Hepatitis B virus, Humans, Liver, Liver Regeneration, Mice, Transgenic, Nucleic Acid Conformation, RNA, Survival Analysis, Karyopherins, RNA Interference, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.